RayzeBio Funding & Investors
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
rayzebio.comTotal Amount Raised: $418,000,000
RayzeBio Funding Rounds
Series D
$160,000,000
Series D Investors
Viking Global InvestorsAlly Bridge GroupLaurion Capital ManagementWellington ManagementSoleus Capital ManagementSofinnovaSands Capital VenturesSeries C
$108,000,000
Series C Investors
LifeSci Venture PartnersLogos CapitalDeerfield ManagementvenBio PartnersVenrock Healthcare Capital PartnersSamsara BioCapitalAlexandria Venture InvestmentsViking Global InvestorsRedmile GroupVersant VenturesAcuta Capital PartnersVivo CapitalCormorant Asset ManagementPerceptive AdvisorsOrbiMed AdvisorsTCG CrossoverSeries B
$105,000,000
Series B Investors
Viking Global InvestorsLogos CapitalLifeSci Venture PartnersRedmile GroupVersant VenturesCormorant Asset ManagementvenBio PartnersOrbiMed AdvisorsVenrock Healthcare Capital PartnersSamsara BioCapitalAlexandria Venture InvestmentsSeries A
$45,000,000
Series A Investors
Versant VenturesvenBio PartnersSamsara BioCapital
Funding info provided by Diffbot.